structure in first source
Also Known As:
ManNPAc; N-phenylacetyl-D-mannosamine
Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Guo, Zhongwu: 4 articles (03/2015 - 03/2006)
2. Wang, Qianli: 3 articles (03/2015 - 12/2007)
3. Zhang, Junping: 3 articles (03/2015 - 12/2007)
4. Qiu, Lei: 2 articles (03/2015 - 11/2012)
5. Wu, Qiuye: 2 articles (03/2015 - 11/2012)
6. Li, Jie: 2 articles (03/2015 - 11/2012)
7. Hu, Zhenlin: 1 article (03/2015)
8. Yu, Shichong: 1 article (03/2015)
9. Li, Yinghua: 1 article (03/2015)
10. Gong, Xi: 1 article (11/2012)

Related Diseases

1. Melanoma (Melanoma, Malignant)
2. Neoplasms (Cancer)
03/10/2015 - "We engineered cancer cells to express an artificial structure, N-phenylacetyl-D-neuraminic acid, in place of the natural N-acetyl-D-neuraminic acid of GM3 by using N-phenylacetyl-D-mannosamine (ManNPhAc) as a biosynthetic precursor. "
03/21/2006 - "Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine."
03/21/2006 - "Because N-phenylacetyl GM3-protein conjugates are particularly immunogenic, the combination of an N-phenylacetyl GM3 conjugate vaccine with systemic N-phenylacetyl-d-mannosamine treatment is a promising immunotherapy for future development and application to melanoma and other GM3-bearing tumors."
11/01/2012 - "Using a murine leukemia model FBL3 with GM3 antigen as the target, it was shown that artificial GM3 N-phenylacetyl derivative (GM3NPhAc) elicited robust antigen-specific T cell-dependent immunity and that N-phenylacetyl-D-mannosamine (ManNPhAc) as the biosynthetic precursor of GM3NPhAc selectively glycoengineered cancer cells to express GM3NPhAc both in vitro and in vivo. "
12/15/2007 - "To verify the principal of a new immunotherapeutic strategy for cancer, a monoclonal antibody 2H3 against N-phenylacetyl GM3, an unnatural form of the tumor-associated antigen GM3, was prepared and employed to demonstrate that murine melanoma cell B16F0 could be effectively glycoengineered by N-phenylacetyl-d-mannosamine to express N-phenylacetyl GM3 and that 2H3 was highly cytotoxic to the glycoengineered B16F0 cell in the presence of complements. "
3. Leukemia

Related Drugs and Biologics

1. Antigens

Related Therapies and Procedures

1. Immunotherapy